# Gene Therapy Sector

Canonical URL: https://biopharmsignal.com/sector/gene-therapy

Gene Therapy includes companies delivering genetic material to correct, replace, silence, or modulate disease-driving biology. This sector page is useful for following businesses exposed to AAV, lentiviral, non-viral, or editing-enabled approaches across rare and broader diseases.

Companies currently grouped under Gene Therapy: 44

## Recent Sector News

- 2026-07-20 07:00 EST — GSK — [European Medicines Agency accepts submission to update Bexsero label for 1-dose Meningitis B booster in 10+ year olds](https://biopharmsignal.com/news/GSK/european-medicines-agency-accepts-submission-to-update-bexsero-label-for-1-dose--8906d096) — Source: GSK plc
- 2026-07-17 09:00 EST — GSK — [GSK provides an update on CALM-1 and CALM-2 phase III trials for camlipixant in refractory chronic cough (RCC)](https://biopharmsignal.com/news/GSK/gsk-provides-an-update-on-calm-1-and-calm-2-phase-iii-trials-for-camlipixant-in--0e112206) — Source: GSK plc
- 2026-07-15 13:40 EST — GSK — [GSK completes acquisition of Nuvalent, Inc.](https://biopharmsignal.com/news/GSK/gsk-completes-acquisition-of-nuvalent-inc-c44954f4) — Source: GSK plc
- 2026-07-13 07:00 EST — GSK — [Jemperli (dostarlimab) achieves sustained clinical complete responses in dMMR/MSI-H locally advanced rectal cancer](https://biopharmsignal.com/news/GSK/jemperli-dostarlimab-achieves-sustained-clinical-complete-responses-in-dmmr-msi--18610cf7) — Source: GSK plc
- 2026-07-10 11:00 EST — GSK — [GSK’s licensor Hansoh Pharma announces positive phase III results for Ris-Rez in China patient population](https://biopharmsignal.com/news/GSK/gsk-s-licensor-hansoh-pharma-announces-positive-phase-iii-results-for-ris-rez-in-b379a2b1) — Source: GSK plc
- 2026-07-09 15:43 EST — CRNX — [Crinetics and Leading Patient Groups Launch ‘Everyday Advocacy’ Initiative to Empower People Across Endocrine Disease Communities | Crinetics](https://biopharmsignal.com/news/CRNX/crinetics-and-leading-patient-groups-launch-everyday-advocacy-initiative-to-empo-2503d5d7) — Source: Crinetics Pharmaceuticals
- 2026-07-09 15:43 EST — CRNX — [Crinetics Presents Full Results From Phase 2 Trial of Atumelnant in Congenital Adrenal Hyperplasia (CAH) in Oral Presentation at ENDO 2026 | Crinetics](https://biopharmsignal.com/news/CRNX/crinetics-presents-full-results-from-phase-2-trial-of-atumelnant-in-congenital-a-cc021e52) — Source: Crinetics Pharmaceuticals
- 2026-07-09 10:00 EST — GSK — [Roy Jakobs to join GSK Board as Non-Executive Director](https://biopharmsignal.com/news/GSK/roy-jakobs-to-join-gsk-board-as-non-executive-director-560f2019) — Source: GSK plc
- 2026-07-06 20:10 EST — CRNX — [Vertex to Acquire Crinetics Pharmaceuticals | Crinetics](https://biopharmsignal.com/news/CRNX/vertex-to-acquire-crinetics-pharmaceuticals-crinetics-29e39d07) — Source: Crinetics Pharmaceuticals
- 2026-07-02 11:00 EST — BCRX — [BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/BCRX/biocryst-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-afb4cc8d) — Source: BioCryst Pharmaceuticals
- 2026-07-01 13:00 EST — SANA — [Sana Biotechnology Announces Symposium Presentation at the European Association for the Study of Diabetes (EASD) Annual Meeting 2026](https://biopharmsignal.com/news/SANA/sana-biotechnology-announces-symposium-presentation-at-the-european-association--26e086a1) — Source: Sana Biotechnology
- 2026-07-01 11:30 EST — ABEO — [Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/ABEO/abeona-therapeutics-announces-new-employee-inducement-grants-under-nasdaq-listin-68d0b897) — Source: Abeona Therapeutics
- 2026-06-30 21:53 EST — CRNX — [Crinetics Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 4, 2026 | Crinetics](https://biopharmsignal.com/news/CRNX/crinetics-pharmaceuticals-to-report-second-quarter-2026-financial-results-on-aug-6cad0f8c) — Source: Crinetics Pharmaceuticals
- 2026-06-30 20:25 EST — SRPT — [Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/SRPT/sarepta-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635--c021b8ab) — Source: Sarepta Therapeutics
- 2026-06-30 12:30 EST — SRPT — [Sarepta Announces FDA Acceptance of sNDAs for AMONDYS 45® and VYONDYS 53®](https://biopharmsignal.com/news/SRPT/sarepta-announces-fda-acceptance-of-sndas-for-amondys-45-and-vyondys-53-40aea7f9) — Source: Sarepta Therapeutics
- 2026-06-29 11:00 EST — BCRX — [BioCryst Sharpens Scientific Focus on External Innovation with Wind Down of Internal Discovery Programs and Closure of Birmingham Research Facility](https://biopharmsignal.com/news/BCRX/biocryst-sharpens-scientific-focus-on-external-innovation-with-wind-down-of-inte-83b84c41) — Source: BioCryst Pharmaceuticals
- 2026-06-25 20:05 EST — REGN — [Regeneron to Report Second Quarter 2026 Financial and Operating Results and Host Conference Call and Webcast](https://biopharmsignal.com/news/REGN/regeneron-to-report-second-quarter-2026-financial-and-operating-results-and-host-c2e371f6) — Source: Regeneron Pharmaceuticals
- 2026-06-25 20:01 EST — TSHA — [Taysha Gene Therapies Announces Multiple Presentations Highlighting its TSHA-102 Clinical Program at the 2026 IRSF Rett Syndrome Scientific Meeting](https://biopharmsignal.com/news/TSHA/taysha-gene-therapies-announces-multiple-presentations-highlighting-its-tsha-102-4055adda) — Source: Taysha Gene Therapies
- 2026-06-25 13:46 EST — TSHA — [Taysha Gene Therapies Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants](https://biopharmsignal.com/news/TSHA/taysha-gene-therapies-announces-pricing-of-public-offering-of-common-stock-and-pre-funded-warrants) — Source: Taysha Gene Therapies
- 2026-06-25 13:46 EST — PASG — [Passage Bio and Remix Therapeutics Announce Merger Agreement](https://biopharmsignal.com/news/PASG/passage-bio-and-remix-therapeutics-announce-merger-agreement) — Source: Passage Bio

## Companies

- [FDMT](https://biopharmsignal.com/company/FDMT) — 4D Molecular Therapeutics
- [ABEO](https://biopharmsignal.com/company/ABEO) — Abeona Therapeutics
- [ADVM](https://biopharmsignal.com/company/ADVM) — Adverum Biotechnologies
- [AMGN](https://biopharmsignal.com/company/AMGN) — Amgen Inc.
- [AVRO](https://biopharmsignal.com/company/AVRO) — AVROBIO
- [BCRX](https://biopharmsignal.com/company/BCRX) — BioCryst Pharmaceuticals
- [BMRN](https://biopharmsignal.com/company/BMRN) — BioMarin Pharmaceutical
- [BLUE](https://biopharmsignal.com/company/BLUE) — bluebird bio, Inc.
- [CCBS](https://biopharmsignal.com/company/CCBS) — Castle Creek Biosciences
- [CRNX](https://biopharmsignal.com/company/CRNX) — Crinetics Pharmaceuticals
- [CRSP](https://biopharmsignal.com/company/CRSP) — CRISPR Therapeutics
- [EDIT](https://biopharmsignal.com/company/EDIT) — Editas Medicine
- [ETON](https://biopharmsignal.com/company/ETON) — Eton Pharmaceuticals
- [EYEN](https://biopharmsignal.com/company/EYEN) — Eyenovia
- [EYPT](https://biopharmsignal.com/company/EYPT) — EyePoint Pharmaceuticals
- [GBIO](https://biopharmsignal.com/company/GBIO) — Generation Bio
- [GNPX](https://biopharmsignal.com/company/GNPX) — Genprex
- [GILD](https://biopharmsignal.com/company/GILD) — Gilead Sciences
- [GRPH](https://biopharmsignal.com/company/GRPH) — Graphite Bio
- [GSK](https://biopharmsignal.com/company/GSK) — GSK plc
- [FIXX](https://biopharmsignal.com/company/FIXX) — Homology Medicines
- [NTLA](https://biopharmsignal.com/company/NTLA) — Intellia
- [KRYS](https://biopharmsignal.com/company/KRYS) — Krystal Biotech
- [MGTX](https://biopharmsignal.com/company/MGTX) — MeiraGTx
- [MRNA](https://biopharmsignal.com/company/MRNA) — Moderna, Inc.
- [EYE](https://biopharmsignal.com/company/EYE) — National Vision
- [NVS](https://biopharmsignal.com/company/NVS) — Novartis AG
- [OMGA](https://biopharmsignal.com/company/OMGA) — Omega Therapeutics
- [PASG](https://biopharmsignal.com/company/PASG) — Passage Bio
- [RLYB](https://biopharmsignal.com/company/RLYB) — Rallybio
- [REGN](https://biopharmsignal.com/company/REGN) — Regeneron Pharmaceuticals
- [RGNX](https://biopharmsignal.com/company/RGNX) — REGENXBIO Inc.
- [RCKT](https://biopharmsignal.com/company/RCKT) — Rocket Pharmaceuticals
- [SANA](https://biopharmsignal.com/company/SANA) — Sana Biotechnology
- [SNY](https://biopharmsignal.com/company/SNY) — Sanofi
- [SRPT](https://biopharmsignal.com/company/SRPT) — Sarepta Therapeutics
- [SEEL](https://biopharmsignal.com/company/SEEL) — Seelos Therapeutics, Inc.
- [SLNO](https://biopharmsignal.com/company/SLNO) — Soleno Therapeutics
- [TSHA](https://biopharmsignal.com/company/TSHA) — Taysha Gene Therapies
- [TVTX](https://biopharmsignal.com/company/TVTX) — Travere Therapeutics
- [RARE](https://biopharmsignal.com/company/RARE) — Ultragenyx Pharmaceutical
- [QURE](https://biopharmsignal.com/company/QURE) — uniQure N.V.
- [VERV](https://biopharmsignal.com/company/VERV) — Verve Therapeutics
- [VYGR](https://biopharmsignal.com/company/VYGR) — Voyager Therapeutics